TrialCurveRezivertinib in EGFR-mutated NSCLC with CNS metastases: reconstructed Kaplan–Meier curves
Rezivertinib in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Central Nervous System Metastasis: Central Nervous System Efficacy from the Phase III REZOR Study. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Cancer Commun (Lond). 2026 Mar 31;46:0018. doi: 10.34133/cancomm.0018 |
|---|---|
| DOI | 10.34133/cancomm.0018 |
| Registry | NCT03866499 |
| Phase | Phase 3 |
| Conditions | NSCLC |
| Interventions | BPI-7711, Gefitinib, Placebo Tablet, Placebo capsule |
| Sponsor | Beta Pharma Shanghai |
| Enrolment | 369 |
| Source licence | Figure published under CC BY 4.0 |
CNS progression-free survival (BICR) — CNS full analysis set (cFAS), n = 159
From figure panel · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: Rezivertinib 24.9 months; Gefitinib 15.1 months. Survival at 12 months: Rezivertinib 72%; Gefitinib 60%. Hazard ratio Rezivertinib vs Gefitinib 0.60 (95% CI 0.36–1.02).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Rezivertinib | 81 | 31 | 24.9 |
| Gefitinib | 78 | 30 | 15.1 |
- Rezivertinib vs Gefitinib: reconstructed HR 0.60 (95% CI 0.36–1.02)
Landmark survival (reconstructed)
| Time | Rezivertinib | Gefitinib |
|---|---|---|
| 6 mo | 88.9% | 77.3% |
| 12 mo | 71.6% | 60.1% |
| 18 mo | 60.4% | 40.0% |
| 24 mo | 51.7% | 40.0% |
Checks against the published figure
- Rezivertinib median: printed 24.9, reconstructed 24.9 pass
- Gefitinib median: printed 15.2, reconstructed 15.1 pass
- hazard ratio (direction inferred): printed 0.58, reconstructed 0.602 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Related trials
- ETER701: Overall survival; Progression-free survival (PFS)
- Socazolimab + chemotherapy in extensive-stage SCLC: Overall survival; Progression-free survival (IRRC, RECIST v1.1)
- KEYNOTE-671 (stage II subgroup): Event-free survival; Overall survival
- PRESERVE-003: Overall survival (OS); Progression-free survival (PFS, investigator assessment)
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials